Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis
Authors' conclusion
Among older adults with RA, JAKi exposure over a median of 1.8 years was not associated with an overall increase in cancer risk. However, lung cancer risk was elevated
Study context
- Population
- Patients with RA age 65 years or older, US SEER-Medicare database, 2014–2019
- Participants
- 12,463 vs 38,345
- Comparison
- Exposure to JAKi, TNFi and other bDMARDs; cancer cases vs cancer-free controls
- Casesn = 12,463
- Controlsn = 38,345reference
- Outcome
- Overall cancer risk associated with JAKi and bDMARD exposure
Methodological detailsSEER-Medicare database, logistic regression
- SEER-Medicare database
- Logistic regression
Main finding
As reported in the abstract
Overall cancer risk
Adjusted odds ratio (95% CI)
JAKi exposure
1.04(0.87–1.26)
TNFi exposure
0.98(0.92–1.05)
Other bDMARD exposure
0.98(0.90–1.07)
Observational data: associations, not effects.
Further findings
JAKi prescription
Lung cancer
| OR (95% CI) | ||
|---|---|---|
| JAKi exposure | 1.40 (1.06–1.87) | |
| JAKi exposure, males | 2.12 (1.14–3.94) | |
| JAKi exposure >2 years | 1.52 (1.01–2.28) | |
| 0.20.5125Odds ratio (log scale) |
Breast cancer, females
| OR (95% CI) | ||
|---|---|---|
| JAKi exposure | 0.62 (0.39–0.97) | |
| 0.20.5125Odds ratio (log scale) |
- JAKi prescription — Median duration of documented JAKi exposure
- 1.8 years
Original publication
Cancer risk of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs among older Americans with rheumatoid arthritis. Rheumatology (Oxford). Published 10 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →